| Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline S Branford, DT Yeung, WT Parker, ND Roberts, L Purins, JA Braley, ... Blood, The Journal of the American Society of Hematology 124 (4), 511-518, 2014 | 221 | 2014 |
| Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease S Branford, P Wang, DT Yeung, D Thomson, A Purins, C Wadham, ... Blood, The Journal of the American Society of Hematology 132 (9), 948-961, 2018 | 180 | 2018 |
| Sensitive detection of BCR-ABL1 mutations in patients with chronic myeloid leukemia after imatinib resistance is predictive of outcome during subsequent therapy WT Parker, RM Lawrence, M Ho, DL Irwin, HS Scott, TP Hughes, ... J Clin Oncol 29 (32), 4250-4259, 2011 | 125 | 2011 |
| A comparative analysis of algorithms for somatic SNV detection in cancer ND Roberts, RD Kortschak, WT Parker, AW Schreiber, S Branford, ... Bioinformatics 29 (18), 2223-2230, 2013 | 120 | 2013 |
| Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients MW Deininger, JG Hodgson, NP Shah, JE Cortes, DW Kim, FE Nicolini, ... Blood, The Journal of the American Society of Hematology 127 (6), 703-712, 2016 | 110 | 2016 |
| Poor response to second-line kinase inhibitors in chronic myeloid leukemia patients with multiple low-level mutations, irrespective of their resistance profile WT Parker, M Ho, HS Scott, TP Hughes, S Branford Blood, The Journal of the American Society of Hematology 119 (10), 2234-2238, 2012 | 85 | 2012 |
| The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib WT Parker, DTO Yeung, AL Yeoman, HK Altamura, BA Jamison, CR Field, ... Blood, The Journal of the American Society of Hematology 127 (15), 1870-1880, 2016 | 72 | 2016 |
| Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell lines: investigating resistance pathways C Tang, L Schafranek, DB Watkins, WT Parker, S Moore, JA Prime, ... Leukemia & lymphoma 52 (11), 2139-2147, 2011 | 72 | 2011 |
| The mutational burden of therapy-related myeloid neoplasms is similar to primary myelodysplastic syndrome but has a distinctive distribution D Singhal, LYA Wee, MM Kutyna, R Chhetri, J Geoghegan, AW Schreiber, ... Leukemia 33 (12), 2842-2853, 2019 | 48 | 2019 |
| Targeted gene panels identify a high frequency of pathogenic germline variants in patients diagnosed with a hematological malignancy and at least one other independent cancer D Singhal, CN Hahn, S Feurstein, LYA Wee, L Moma, MM Kutyna, ... Leukemia 35 (11), 3245-3256, 2021 | 40 | 2021 |
| BAM-matcher: a tool for rapid NGS sample matching PPS Wang, WT Parker, S Branford, AW Schreiber Bioinformatics 32 (17), 2699-2701, 2016 | 38 | 2016 |
| A tale of two siblings: two cases of AML arising from a single pre-leukemic DNMT3A mutant clone CN Hahn, DM Ross, J Feng, A Beligaswatte, DK Hiwase, WT Parker, ... Leukemia 29 (10), 2101-2104, 2015 | 35 | 2015 |
| Many BCR-ABL1 compound mutations reported in chronic myeloid leukemia patients may actually be artifacts due to PCR-mediated recombination WT Parker, SR Phillis, DTO Yeung, TP Hughes, HS Scott, S Branford Blood, The Journal of the American Society of Hematology 124 (1), 153-155, 2014 | 28 | 2014 |
| Ponatinib tyrosine kinase inhibitor induces a thromboinflammatory response A Hamadi, AP Grigg, G Dobie, KL Burbury, AP Schwarer, FA Kwa, ... Thrombosis and haemostasis 119 (07), 1112-1123, 2019 | 25 | 2019 |
| De novo UBE2A mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways V Magistroni, M Mauri, D D’Aliberti, C Mezzatesta, I Crespiatico, M Nava, ... haematologica 104 (9), 1789, 2019 | 23 | 2019 |
| BCR-ABL1 kinase domain mutations may persist at very low levels for many years and lead to subsequent TKI resistance WT Parker, AL Yeoman, BA Jamison, DT Yeung, HS Scott, TP Hughes, ... British journal of cancer 109 (6), 1593-1598, 2013 | 22 | 2013 |
| Any BCR-ABL reduction below 10% at 6 months of therapy significantly improves outcome for CML patients with a poor response at 3 months S Branford, N Roberts, DT Yeung, H Altamura, WT Parker, TP Hughes Blood 122 (21), 254, 2013 | 21 | 2013 |
| ASXL1 and BIM germ line variants predict response and identify CML patients with the greatest risk of imatinib failure JE Marum, DT Yeung, L Purins, J Reynolds, WT Parker, D Stangl, ... Blood Advances 1 (18), 1369-1381, 2017 | 20 | 2017 |
| Molecular methods in diagnosis and monitoring of haematological malignancies DT Yeung, WT Parker, S Branford Pathology-Journal of the RCPA 43 (6), 566-579, 2011 | 18 | 2011 |
| The adverse effect of high sokal risk for first line imatinib treated patients is overcome by a rapid rate of BCR-ABL decline measured as early as 1 month of treatment S Branford, DT Yeung, DM Ross, WT Parker, J Braley, JF Seymour, ... Blood 124 (21), 816, 2014 | 10 | 2014 |
